Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis

BACKGROUND: Tofacitinib and other new treatments approved for use in psoriatic arthritis have only recently been included in psoriatic arthritis treatment guidelines, and studies evaluating the relative efficacy of available therapies are important to inform treatment decisions by healthcare profess...

Descripción completa

Detalles Bibliográficos
Autores principales: Gladman, Dafna D., Orbai, Ana-Maria, Gomez-Reino, Juan, Chang-Douglass, Stacey, Leoncini, Emanuele, Burton, Hannah E., Kanik, Keith S., Romero, Ana Belen, Cappelleri, Joseph C., Hsu, Ming-Ann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7494680/
https://www.ncbi.nlm.nih.gov/pubmed/32983284
http://dx.doi.org/10.1016/j.curtheres.2020.100601

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7494680/
https://www.ncbi.nlm.nih.gov/pubmed/32983284
http://dx.doi.org/10.1016/j.curtheres.2020.100601

Ejemplares similares